467 related articles for article (PubMed ID: 22214450)
1. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.
Bařinka C; Rojas C; Slusher B; Pomper M
Curr Med Chem; 2012; 19(6):856-70. PubMed ID: 22214450
[TBL] [Abstract][Full Text] [Related]
2. N-acetylaspartylglutamate (NAAG) and glutamate carboxypeptidase II: An abundant peptide neurotransmitter-enzyme system with multiple clinical applications.
Neale JH; Yamamoto T
Prog Neurobiol; 2020 Jan; 184():101722. PubMed ID: 31730793
[TBL] [Abstract][Full Text] [Related]
3. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer.
Mesters JR; Barinka C; Li W; Tsukamoto T; Majer P; Slusher BS; Konvalinka J; Hilgenfeld R
EMBO J; 2006 Mar; 25(6):1375-84. PubMed ID: 16467855
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationships of glutamate carboxypeptidase II (GCPII) inhibitors.
Ferraris DV; Shukla K; Tsukamoto T
Curr Med Chem; 2012; 19(9):1282-94. PubMed ID: 22304717
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease.
Evans JC; Malhotra M; Cryan JF; O'Driscoll CM
Br J Pharmacol; 2016 Nov; 173(21):3041-3079. PubMed ID: 27526115
[TBL] [Abstract][Full Text] [Related]
6. Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury.
Gao Y; Xu S; Cui Z; Zhang M; Lin Y; Cai L; Wang Z; Luo X; Zheng Y; Wang Y; Luo Q; Jiang J; Neale JH; Zhong C
J Neurochem; 2015 Jul; 134(2):340-53. PubMed ID: 25872793
[TBL] [Abstract][Full Text] [Related]
7. Expression of glutamate carboxypeptidase II in human brain.
Sácha P; Zámecník J; Barinka C; Hlouchová K; Vícha A; Mlcochová P; Hilgert I; Eckschlager T; Konvalinka J
Neuroscience; 2007 Feb; 144(4):1361-72. PubMed ID: 17150306
[TBL] [Abstract][Full Text] [Related]
8. Regulation of glutamate carboxypeptidase II hydrolysis of N-acetylaspartylglutamate (NAAG) in crayfish nervous tissue is mediated by glial glutamate and acetylcholine receptors.
Urazaev AK; Grossfeld RM; Lieberman EM
J Neurochem; 2005 May; 93(3):605-10. PubMed ID: 15836619
[TBL] [Abstract][Full Text] [Related]
9. Detection and quantitation of glutamate carboxypeptidase II in human blood.
Knedlík T; Navrátil V; Vik V; Pacík D; Šácha P; Konvalinka J
Prostate; 2014 May; 74(7):768-80. PubMed ID: 24647901
[TBL] [Abstract][Full Text] [Related]
10. A role for the locus coeruleus in the analgesic efficacy of N-acetylaspartylglutamate peptidase (GCPII) inhibitors ZJ43 and 2-PMPA.
Nonaka T; Yamada T; Ishimura T; Zuo D; Moffett JR; Neale JH; Yamamoto T
Mol Pain; 2017 Jan; 13():1744806917697008. PubMed ID: 28326936
[TBL] [Abstract][Full Text] [Related]
11. Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate.
Bacich DJ; Ramadan E; O'Keefe DS; Bukhari N; Wegorzewska I; Ojeifo O; Olszewski R; Wrenn CC; Bzdega T; Wroblewska B; Heston WD; Neale JH
J Neurochem; 2002 Oct; 83(1):20-9. PubMed ID: 12358725
[TBL] [Abstract][Full Text] [Related]
12. NAAG peptidase inhibitors and their potential for diagnosis and therapy.
Zhou J; Neale JH; Pomper MG; Kozikowski AP
Nat Rev Drug Discov; 2005 Dec; 4(12):1015-26. PubMed ID: 16341066
[TBL] [Abstract][Full Text] [Related]
13. Glutamate carboxypeptidase II does not process amyloid-β peptide.
Sedlák F; Šácha P; Blechová M; Březinová A; Šafařík M; Šebestík J; Konvalinka J
FASEB J; 2013 Jul; 27(7):2626-32. PubMed ID: 23525279
[TBL] [Abstract][Full Text] [Related]
14. Blockade of N-acetylaspartylglutamate peptidases: a novel protective strategy for brain injuries and neurological disorders.
Zhong C; Luo Q; Jiang J
Int J Neurosci; 2014 Dec; 124(12):867-73. PubMed ID: 24494725
[TBL] [Abstract][Full Text] [Related]
15. Still NAAG'ing After All These Years: The Continuing Pursuit of GCPII Inhibitors.
Vornov JJ; Hollinger KR; Jackson PF; Wozniak KM; Farah MH; Majer P; Rais R; Slusher BS
Adv Pharmacol; 2016; 76():215-55. PubMed ID: 27288079
[TBL] [Abstract][Full Text] [Related]
16. NAAG Peptidase Inhibitors Act via mGluR3: Animal Models of Memory, Alzheimer's, and Ethanol Intoxication.
Olszewski RT; Janczura KJ; Bzdega T; Der EK; Venzor F; O'Rourke B; Hark TJ; Craddock KE; Balasubramanian S; Moussa C; Neale JH
Neurochem Res; 2017 Sep; 42(9):2646-2657. PubMed ID: 28285415
[TBL] [Abstract][Full Text] [Related]
17. Glutamate carboxypeptidase II is not an amyloid peptide-degrading enzyme.
Alt J; Stathis M; Rojas C; Slusher B
FASEB J; 2013 Jul; 27(7):2620-5. PubMed ID: 23525278
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents.
Kozikowski AP; Zhang J; Nan F; Petukhov PA; Grajkowska E; Wroblewski JT; Yamamoto T; Bzdega T; Wroblewska B; Neale JH
J Med Chem; 2004 Mar; 47(7):1729-38. PubMed ID: 15027864
[TBL] [Abstract][Full Text] [Related]
19. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity.
Barinka C; Sácha P; Sklenár J; Man P; Bezouska K; Slusher BS; Konvalinka J
Protein Sci; 2004 Jun; 13(6):1627-35. PubMed ID: 15152093
[TBL] [Abstract][Full Text] [Related]
20. Deletion of glutamate carboxypeptidase II (GCPII), but not GCPIII, provided long-term benefits in mice with traumatic brain injury.
Ji T; Pang Y; Cheng M; Wang R; Chen X; Zhang C; Liu M; Zhang J; Zhong C
CNS Neurosci Ther; 2023 Dec; 29(12):3786-3801. PubMed ID: 37349952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
